
Opinion|Videos|April 21, 2025
Important Takeaways Regarding the Utilization of Ruxolitinib
Author(s)Gary M. Owens, MD , Lawrence Eichenfield, MD
Panelists discuss how ruxolitinib offers significant advantages in atopic dermatitis management through its targeted JAK inhibition mechanism, demonstrating rapid and sustained improvement in itch and lesions, effectiveness across various disease severities and body regions, favorable safety profile compared to systemic alternatives, and potential for reduced healthcare resource utilization over extended treatment periods.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
2
Alyana Samai, M.P.H. | 2026 MHE Emerging Leaders in Healthcare
3
Brukinsa provides long-term disease control in chronic lymphocytic leukemia
4
FDA approves Differin Epiduo Acne Gel for over-the-counter use
5

























